Search Results for "Onglyza"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Onglyza. Results 1 to 10 of 15 total matches.
See also: saxagliptin

Saxagliptin (Onglyza) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009  (Issue 1324)
Saxagliptin (Onglyza) for Type 2 Diabetes ...
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Med Lett Drugs Ther. 2009 Nov 2;51(1324):85-6 |  Show IntroductionHide Introduction

Dapagliflozin/Saxagliptin (Qtern) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018  (Issue 1543)
) and the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin (Onglyza), for oral treatment of adults with type 2 ...
The FDA has approved Qtern (AstraZeneca), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) and the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin (Onglyza), for oral treatment of adults with type 2 diabetes. Dapagliflozin and saxagliptin have each been available for years alone and in combination with extended-release metformin (Xigduo XR; Kombiglyze XR). Three SGLT2/DPP-4 inhibitor combinations are now available in the US (see Table 2).
Med Lett Drugs Ther. 2018 Mar 26;60(1543):55-6 |  Show IntroductionHide Introduction

Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2011  (Issue 1367)
(Onglyza) for type 2 diabetes. Med Lett Drugs Ther 2009; 51:85. 4. S Del Prato et al. Effect ...
Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a third oral dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, was recently approved by the FDA for treatment of type 2 diabetes, either alone or in combination with metformin, a sulfonylurea or pioglitazone
Med Lett Drugs Ther. 2011 Jun 27;53(1367):49-50 |  Show IntroductionHide Introduction

What Comes After Metformin for Type 2 Diabetes?

   
The Medical Letter on Drugs and Therapeutics • Jul 23, 2012  (Issue 1395)
Linagliptin – Tradjenta Weight neutral Less effective than sulfonylureas 210.00 Saxagliptin – Onglyza or GLP ...
Most experts agree that lifestyle modifications and metformin (Glucophage, and others) should be used first to treat patients with type 2 diabetes. If metformin alone fails to control hyperglycemia, there is no general agreement on which drug should be added next. A recent article in The Medical Letter offered some support for a sulfonylurea. Three recent trials published in The Lancet favored the long-acting basal insulin glargine, the glucagon-like peptide (GLP-1) analog exenatide, and the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, respectively. Some of the advantages...
Med Lett Drugs Ther. 2012 Jul 23;54(1395):58-9 |  Show IntroductionHide Introduction

Saxagliptin/Metformin (Kombiglyze XR) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2011  (Issue 1360)
; 6:47. 2. Saxagliptin (Onglyza) for type 2 diabetes. Med Lett Drugs Ther 2009; 51:85. 3. AJ Scheen ...
Metformin (Glucophage, and others) is generally preferred as the first-line agent for treatment of type 2 diabetes, but most patients subsequently require treatment with more than one drug. Many combination products have been marketed; the latest of these combines saxagliptin with extended-release (ER) metformin as Kombiglyze XR.
Med Lett Drugs Ther. 2011 Mar 21;53(1360):21-2 |  Show IntroductionHide Introduction

Linagliptin/Metformin (Jentadueto) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 14, 2012  (Issue 1390)
sitagliptin (Januvia) and saxagliptin (Onglyza).2 Both sitagliptin and saxagliptin are also available ...
Linagliptin (Tradjenta) and metformin (Glucophage, and others) are now available as a fixed-dose combination (Jentadueto – Boehringer Ingelheim/Lilly) for oral treatment of type 2 diabetes in adults. Metformin is generally the preferred first-line agent for treatment of type 2 diabetes, but most patients eventually require treatment with multiple drugs. Linagliptin is a dipeptidyl peptidase-4 (DDP-4) inhibitor like sitagliptin (Januvia) and saxagliptin (Onglyza). Both sitagliptin and saxagliptin are also available in fixed-dose combinations with...
Med Lett Drugs Ther. 2012 May 14;54(1390):37-9 |  Show IntroductionHide Introduction

Glyxambi - A New Combination for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015  (Issue 1467)
/Lilly) 5 mg tabs 5 mg once daily 330.70 Saxagliptin – Onglyza (AstraZeneca) 2.5, 5 mg tabs 5 mg once ...
The FDA has approved Glyxambi (Boehringer Ingelheim/Lilly), a fixed-dose combination of empagliflozin (Jardiance) and linagliptin (Tradjenta), for oral treatment of type 2 diabetes in adults. It is the first combination of a sodium-glucose co-transporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor to be approved in the US.
Med Lett Drugs Ther. 2015 Apr 27;57(1467):65-6 |  Show IntroductionHide Introduction

Alogliptin (Nesina) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 27, 2013  (Issue 1417)
in the US. The other three – saxagliptin (Onglyza), sitagliptin (Januvia), and linagliptin (Tradjenta) – are also available ...
The FDA has approved the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (Nesina – Takeda) for treatment of type 2 diabetes. In addition to the single-ingredient product, the FDA also approved fixed-dose combinations of alogliptin/metformin (Kazano) and alogliptin/pioglitazone (Oseni) for the same indication. Alogliptin is the fourth DPP-4 inhibitor to become available in the US. The other three – saxagliptin (Onglyza), sitagliptin (Januvia), and linagliptin (Tradjenta) – are also available in fixed-dose combinations with metformin.
Med Lett Drugs Ther. 2013 May 27;55(1417):41-3 |  Show IntroductionHide Introduction

Jentadueto XR for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Aug 01, 2016  (Issue 1500)
once/d 357.10 Ingelheim/Lilly) Saxagliptin – Onglyza (AstraZeneca) 2.5, 5 mg tabs 5 mg PO once/d6 ...
The FDA has approved Jentadueto XR (Boehringer Ingelheim/Lilly), a once-daily extended-release formulation of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the biguanide metformin, for oral treatment of type 2 diabetes. Linagliptin and metformin have been available for years in a twice-daily immediate-release combination (Jentadueto). Once-daily extended-release formulations combining metformin with the DPP-4 inhibitors saxagliptin (Kombiglyze XR) and sitagliptin (Janumet XR) are also available.
Med Lett Drugs Ther. 2016 Aug 1;58(1500):98-100 |  Show IntroductionHide Introduction

Canagliflozin (Invokana) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 13, 2013  (Issue 1416)
Weight neutral Less effective than sulfonylureas 240.00 Saxagliptin – Onglyza or GLP-1 analogs ...
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes.
Med Lett Drugs Ther. 2013 May 13;55(1416):37-9 |  Show IntroductionHide Introduction